Press Releases

Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate (multikinase inhibitor, product name: LENVIMA , "lenvatinib") and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN , "eribulin") will be given at the American Society of Clinical Oncology (ASCO20 Virtual Scientific Program(1)), from May 29 to 31, 2020. At this year's meeting, the final res

Cardiff Oncology, Inc., a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and leukemia, today announced an agreement with PoC Capital, LLC, to fund the completion of its ongoing Phase 1b/2 clinical trial in patients with KRAS-mutated metastatic Colorectal Cancer (mCRC). "We are pleased to be able to support the

As more and more laboratories are coming online to combat COVID19, Neutec Group has been able to support the effort by providing laboratory automation enabling the necessary large-scale output required for testing. Neutec Group’s tube and bottle fillers have been in incredibly high demand as they allow for versatility and much needed scaling at this time of urgency and opportunity. “We at Neutec are pleased to be able to help in the fight against COVID19,” states R

BioMed X, an independent research institute that identifies big biomedical research challenges and provides innovative solutions by combining global crowdsourcing with local incubation, announces today the launch of its new Rapid Antiviral Response Platform (RAR). In response to the devastating COVID-19 pandemic, BioMed X strives to develop an arsenal of ultrafast new antiviral drug discovery, development and mass-manufacturing tools that will allow to go from the identification of

Gamida Cell Ltd., an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced positive topline results from its Phase 3 clinical study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of bone marrow transplant. The median time to neutrophil engraftment was 12 days for patients randomized to omidubicel compared t

Frazier Healthcare Partners (“Frazier”)  announced the launch of Lengo Therapeutics, Inc. (“Lengo”), a biopharmaceutical company focused on the discovery and development of novel treatments targeting driver mutations in oncology. “Lengo emerged from discussions at Frazier and among a highly experienced group of oncology researchers, including Frazier Senior Advisors Roger Ulrich, Ph.D., Jim Bristol, Ph.D., Michael Gallatin, Ph.D. and Bruce Roth, Ph

The U.S. Food and Drug Administration took important actions to help accelerate the development of prevention and treatment options for COVID-19 by providing new guidance with recommendations for innovators and researchers conducting work in this area. These guidance documents aim to make the process for submitting applications to initiate studies for new drugs and biological products more efficient and outline recommendations for ways to design clinical trials to evaluate safety and effectiv

SIRIO Europe (Ayanda) – the European headquarters of the SIRIO Group, a global nutraceutical contract development, innovation and manufacturing organization (CDiMO) – says considerable worldwide demand for immunity products has accelerated in recent months due coronavirus, but it is also likely to deliver a permanent ‘new norm’ of higher growth. “Already in Europe, we have seen a significant spike in the demand for immunity products across the main econ

Under the patronage of H.H. Sheikh Hamdan Bin Rashid Al Maktoum, Deputy Ruler of Dubai, UAE Minister of Finance and President of Dubai Health Authority. Due to the growing concern around the coronavirus (COVID-19), and in alignment with best practices laid out by theHealth Ministry of UAE, World Health Organization, and other relevant entities, the organising committee of Physio 2020 conference has decided to run the event as a virtual event from 12 – 13th June 2020.

The U.S. Food and Drug Administration approved Retevmo (selpercatinib) capsules to treat three types of tumors – non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers – in patients whose tumors have an alteration (mutation or fusion) in a specific gene (RET or "rearranged during transfection"). Retevmo is the first therapy approved specifically for cancer patients with the RET gene alterations. "Innovations in gene-specifi